Advertisement|Remove ads.

Sarepta Therapeutics Inc. (SRPT) on Wednesday released initial results from two investigational programs targeting genetic muscle diseases, demonstrating encouraging safety and biological activity in early trials.
The findings suggest the company’s approach may overcome longstanding delivery challenges in RNA therapies.
The therapies, identified as SRP-1001 and SRP-1003, are being studied for facioscapulohumeral muscular dystrophy type 1 and myotonic dystrophy type 1, respectively.
Following the update, Sarepta stock traded over 3% higher in Wednesday’s premarket.
Get updates to this developing story directly on Stocktwits.